修改后的C型尿酸使瘤血管正常化,重振抗瘤免疫力,并改善固体瘤治疗方法
Zhen Lu1, Ioannis Verginadis2, Motofumi Kumazoe3
1Department of Biomedical Sciences, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
一种新的C型性尿素衍生物 (dCNP) 能使瘤血管正常化,减少缺氧并提高抗癌疗法的疗效. 这种方法改善了瘤 perfusion 和免疫反应,提供了对固体瘤的新策略.
科学领域:
- 在瘤学瘤学.
- 血管生物学 血管生物学
- 免疫学 免疫学 免疫学
背景情况:
- 瘤微环境 (TME) 缺氧和泄漏的血管系统损害了抗癌治疗.
- 功能障碍的瘤血管生成导致缺氧,代谢问题和免疫抑制.
- 目前的疗法经常与TME异常作斗争.
研究的目的:
- 为了研究一种基于激动剂的新方法来规范瘤血管系统.
- 在固体瘤模型中评估C型尿性衍生物 (dCNP) 的疗效.
- 评估dCNP对瘤缺氧,免疫反应和治疗结果的影响.
主要方法:
- 用dCNP治疗各种小鼠固体瘤模型 (结肠,胰腺).
- 分析瘤组织中的基因表达特征.
- 评估瘤血管功能,缺氧,间歇性液体压力和免疫细胞透.
- 评估dCNP与化疗,放射治疗和免疫治疗结合使用.
主要成果:
- 在多种瘤模型中,dCNP治疗使瘤血管正常化,减少缺氧.
- dCNP抑制了电流生成,细胞外矩阵重塑,并降低了间歇性流体压力.
- 经过dCNP治疗,可以恢复抗瘤免疫反应,抑制瘤生长和转移.
- 将dCNP与其他疗法结合,显著提高了它们对固体瘤的疗效.
结论:
- dCNP显示出作为一流的血管正常化激素对固体瘤的潜在潜力.
- 这种方法可以改善瘤输液,减少缺氧,增强抗瘤免疫力.
- dCNP代表了克服与TME相关的治疗耐药性的有希望的策略.
更多相关视频
08:52Intravital Microscopy of Tumor-associated Vasculature Using Advanced Dorsal Skinfold Window Chambers on Transgenic Fluorescent Mice
Published on: January 19, 2018
11:02Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
相关概念视频
Tumor Immunotherapy
Targeted Cancer Therapies
There are several types of targeted therapies against...
The Tumor Microenvironment
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
Mechanism of Angiogenesis
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
